From: Characteristics and outcomes of the drug patent linkage system in China
Registration year | 2021 (Before July 4) | 2021 (After July 4) | 2022 | 2023 (First half) | Total |
---|---|---|---|---|---|
Number of drugs (N) | 256 | 204 | 97 | 75 | 632 |
Drug approval time, no. (%) | |||||
In registration year | 23(9) | 50(24.5) | 54(55.7) | 43(57.3) | 170(26.9) |
Prior to registration year | 233(91) | 154(75.5) | 43(44.3) | 32(42.7) | 462(73.1) |
MAH type, no. (%) | |||||
Foreign | 181(70.7) | 79(38.7) | 50(51.5) | 26(34.7) | 336(53.2) |
Domestic | 75(29.3) | 125(61.3) | 47(48.5) | 49(65.3) | 296(46.8) |
Administration, no. (%) | |||||
Oral | 215(84) | 125(61.3) | 61(62.9) | 51(68) | 452(71.5) |
Injection | 23(9) | 60(29.4) | 31(32) | 20(26.7) | 134(21.2) |
Others | 18(7) | 19(9.3) | 5(5.1) | 4(5.3) | 46(7.3) |
Legal status of patent, no. (%) | |||||
Valid | 235(91.8) | 192(94.1) | 92(94.8) | 75(100) | 594(94) |
Partially valid | 8(3.1) | 9(4.4) | 0(0) | 0(0) | 17(2.7) |
Terminated or invalidated | 13(5.1) | 3(1.5) | 5(5.2) | 0(0) | 21(3.3) |